What Is CJC-1295 in Research?

CJC-1295 is a synthetic growth hormone-releasing hormone-related peptide analog developed from the active N-terminal region of human growth hormone-releasing factor. In the original research literature, CJC-1295 refers to a modified hGRF(1-29) analog containing four amino-acid substitutions and an additional C-terminal lysine carrying a reactive maleimide-containing group designed for covalent association with circulating albumin. This defined molecular structure should be distinguished from native GHRH, unmodified GRF(1-29), Modified GRF (1-29), and the informal commercial phrase “CJC-1295 without DAC.”

These identity distinctions form the foundation of CJC-1295 Research. Research coverage should identify the exact peptide sequence and modification state before comparing receptor pharmacology, degradation, albumin association, pharmacokinetics, or model findings.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

CJC-1295 Is a Defined Synthetic Peptide Analog

CJC-1295 is not a general name for every growth hormone-releasing hormone analog.

The original compound was described through a specific combination of:

• a GRF(1-29)-related peptide backbone
• four amino-acid substitutions
• a C-terminal lysine extension
• a maleimide-containing reactive group
• albumin-binding chemistry

These structural features are part of the compound's research identity.

What Is GHRH?

Growth hormone-releasing hormone, abbreviated GHRH, is an endogenous hypothalamic peptide involved in signalling through the growth hormone-releasing hormone receptor.

Human GHRH has historically been described in several closely related forms according to peptide processing and sequence length.

Research terminology may include:

• GHRH
• GRF
• hGRF
• GHRH(1-44)
• GRF(1-29)

These terms require context because they do not all refer to the same synthetic analog.

What Does GRF Mean?

GRF stands for growth hormone-releasing factor.

Older and modern literature may use GRF and GHRH terminology in overlapping ways.

The term should therefore be interpreted according to:

• species
• sequence
• residue numbers
• source material
• experimental context

What Is hGRF(1-29)?

hGRF(1-29) refers to the first 29 amino-acid residues of human growth hormone-releasing factor.

This N-terminal region contains the sequence information required for receptor-associated activity in classic GHRH research.

CJC-1295 was developed from this shorter peptide framework rather than simply reproducing the complete endogenous GHRH sequence.

CJC-1295 Is Not Native hGRF(1-29)

The peptide backbone used for CJC-1295 contains substitutions relative to native hGRF(1-29).

The original discovery literature described changes at several positions within the 29-residue sequence.

These substitutions were incorporated as part of the synthetic analog design.

Why Amino-Acid Substitutions Matter

Changing even one amino-acid residue can alter peptide properties.

Potentially affected variables include:

• protease susceptibility
• chemical stability
• receptor interaction
• conformation
• hydrophobicity
• chromatographic behaviour
• mass-spectrometric fragmentation

A substituted analog should therefore remain analytically distinct from the parent sequence.

The Four-Substitution Backbone

The original CJC-1295 research describes a tetrasubstituted GRF(1-29)-related peptide.

The substitutions help distinguish the synthetic analog from native human GRF(1-29).

A research record should ideally identify:

• the complete sequence
• substituted residue positions
• terminal structure
• additional conjugated groups

CJC-1295 Contains an Additional C-Terminal Modification

The structure identified as CJC-1295 in the original research includes more than the modified 29-residue backbone.

A lysine residue carrying a maleimide-containing reactive group was incorporated at the C-terminal region.

This feature is central to the distinction between CJC-1295 and Modified GRF (1-29).

Why the Maleimide Group Matters

Maleimide chemistry can react with thiol groups under suitable conditions.

In the CJC-1295 design, this chemistry was used to permit covalent association with circulating albumin after introduction into the experimental system.

This represents a molecular design feature rather than a separate peptide ingredient.

Albumin Association Is Part of the Original Design

The original CJC-1295 literature investigated covalent association between the modified peptide and endogenous serum albumin.

Researchers examined this using methods including:

• plasma analysis
• immunoreactive detection
• protein-associated bands
• pharmacokinetic measurements

Albumin association should remain a measured molecular and pharmacokinetic property rather than a generalized product claim.

What Is Albumin?

Albumin is a major circulating plasma protein.

It contains structural features capable of interacting with many endogenous and synthetic molecules.

Research involving peptide-albumin association can examine:

• binding chemistry
• covalent attachment
• circulating molecular forms
• analytical recovery
• distribution

Covalent and Non-Covalent Association Are Different

Some peptide designs associate with albumin through reversible non-covalent interactions.

The original CJC-1295 strategy was described through reactive chemistry capable of forming a covalent albumin-associated species.

These mechanisms should not be treated as interchangeable.

Why CJC-1295 Was Called a Long-Acting Analog

Early papers used the term long-acting to describe the observed persistence of compound-associated material and downstream pharmacodynamic measurements relative to shorter GHRH-related peptides.

In research writing, long-acting should therefore be interpreted through measured variables such as:

• concentration-time profiles
• albumin association
• apparent half-life
• duration of measured pharmacodynamic responses

The phrase does not independently establish suitability for any use.

Pharmacokinetics Is Separate From Molecular Identity

Molecular identity describes what compound is present.

Pharmacokinetics describes how compound-associated concentrations change over time in a defined model.

Relevant pharmacokinetic measurements can include:

• concentration
• time to observed peak
• area under the concentration-time curve
• apparent half-life
• clearance-related estimates

A Longer Measured Half-Life Does Not Define the Entire Compound

Half-life is one pharmacokinetic parameter.

It does not establish:

• molecular identity
• receptor potency
• purity
• formulation
• clinical effectiveness
• general safety

CJC-1295 Acts Through the GHRH Receptor System

CJC-1295 was designed and investigated as a GHRH receptor-related agonist.

Research systems may evaluate:

• receptor-associated signalling
• pituitary cell responses
• growth hormone measurements
• downstream IGF-I measurements

These are pharmacological and endocrine research endpoints.

What Is the GHRH Receptor?

The growth hormone-releasing hormone receptor is a G-protein-coupled receptor expressed prominently in pituitary somatotroph-associated biology.

Receptor research can examine:

• ligand binding
• cyclic AMP-associated signalling
• receptor expression
• ligand potency
• cell-specific responses

Receptor Agonism Does Not Establish a Clinical Outcome

Demonstrating that a peptide activates the GHRH receptor establishes receptor pharmacology under the conditions studied.

It does not independently establish:

• a therapeutic benefit
• a clinical outcome
• personal-use suitability
• a recommended amount

Growth Hormone Measurements Are Research Endpoints

Some CJC-1295 studies measured circulating growth hormone after exposure to the investigational compound.

Such studies may report:

• concentration-time curves
• peak measurements
• pulse-related parameters
• area under the curve

These measurements should remain identified as hormone endpoints rather than being transformed into general benefit claims.

IGF-I Is a Separate Downstream Measurement

CJC-1295 studies have also measured insulin-like growth factor I.

IGF-I concentration is a different endpoint from:

• CJC-1295 concentration
• GHRH receptor activation
• growth hormone concentration
• clinical outcomes

These measures should not be collapsed into one generalized response.

Hormone Concentration Does Not Describe an Entire Endocrine System

Endocrine signalling depends on:

• secretion patterns
• receptor sensitivity
• binding proteins
• feedback pathways
• tissue responses
• time of measurement

A single hormone measurement therefore represents one component of the system.

Pulsatility Is Another Research Variable

Growth hormone is normally released in pulses.

CJC-1295 research has examined whether pulsatile patterns remain detectable during prolonged GHRH-receptor stimulation.

Pulsatility analysis can involve:

• sampling frequency
• pulse detection algorithms
• pulse amplitude
• pulse frequency
• baseline secretion

Pulsatility Research Is Not Personal-Use Guidance

Observing a hormone secretion pattern in a controlled study does not establish a recommended protocol for use outside that research setting.

CJC-1295 Has Been Studied in Animal Models

Preclinical research includes studies in rodents and other experimental systems.

Animal models can investigate:

• albumin association
• pharmacokinetics
• pituitary responses
• growth hormone measurements
• model-specific physiological variables

Animal findings should remain species and model specific.

CJC-1295 Has Also Appeared in Human Research

Published studies investigated CJC-1295 in controlled human research settings.

Those studies were designed around defined:

• eligibility criteria
• investigational preparations
• sampling schedules
• pharmacokinetic endpoints
• pharmacodynamic endpoints
• adverse-event monitoring

The existence of those studies does not convert their protocol into personal-use guidance.

The Investigational Preparation Matters

A controlled study uses a characterized investigational material.

A separately sourced product carrying the same name cannot automatically be assumed to have the same:

• sequence
• albumin-binding modification
• purity
• formulation
• impurity profile

A Product Label Does Not Establish CJC-1295 Identity

The name CJC-1295 on a label should ideally correspond to the molecular structure established in the original literature.

Identity verification may require:

• sequence information
• molecular mass
• modification confirmation
• chromatographic analysis
• mass spectrometry

CJC-1295 Is Not a Generic Name for Modified GRF (1-29)

Modified GRF (1-29) refers to a related tetrasubstituted 29-residue GHRH analog without the additional albumin-binding C-terminal modification characteristic of CJC-1295 in the original literature.

This distinction becomes important when reading commercial or secondary terminology.

Why “CJC-1295 Without DAC” Can Be Confusing

The phrase “CJC-1295 without DAC” is often used outside the original development literature for Modified GRF (1-29).

However, removing the albumin-binding modification removes a defining structural feature of the compound originally called CJC-1295.

For rigorous research writing, the exact peptide should therefore be named directly.

DAC Is Not a Separate Peptide

In CJC-1295 terminology, DAC is associated with the albumin-binding design concept.

It should not be interpreted as:

• another hormone
• another receptor agonist
• a second peptide ingredient

CJC-1295 and Native GHRH Are Not the Same Molecule

CJC-1295 derives from GHRH-related sequence biology but contains structural modifications not found in native human GHRH.

The distinction between the endogenous peptide and synthetic analog is examined in CJC-1295 vs GHRH: Why the Terms Are Not Interchangeable.

Reading the Original Molecular-Design Research

The PubMed-indexed study Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog describes CJC-1295 as a tetrasubstituted hGRF(1-29) analog containing an added C-terminal lysine derivative capable of albumin bioconjugation.

This study is useful for defining the original molecular identity and research rationale of CJC-1295. Its animal pharmacology findings should not be interpreted as evidence that a CJC-1295-labelled product is effective, safe, appropriate, or advisable for personal use.

Final Perspective

CJC-1295 is a defined synthetic GHRH-related peptide analog based on a modified hGRF(1-29) sequence and an additional albumin-binding structural modification.

The original research identity therefore contains more information than the phrase GHRH analog alone.

Accurate research coverage should identify the exact sequence, substitutions, C-terminal modification, albumin-binding design, receptor system, analytical method, and study model without treating CJC-1295 as interchangeable with native GHRH, Modified GRF (1-29), or loosely labelled “CJC-1295 without DAC” materials.